Ultragenyx wins priority review for burosumab; Genfit raising €150M for PhIII NASH study
→ Ultragenyx $RARE and its partners at Kyowa Hakko Kirin landed a priority review for burosumab to treat pediatric and adult patients with X-Linked Hypophosphatemia. The accelerated PR gives them a shot at an April 17, 2018 PDUFA date.
→ Genfit (Euronext: GNFT) is raising €150 million so it can wrap up its Phase III for elafibranor in NASH and take the data to regulators.
→ France’s Biophytis has raised €10.4 million for mid-stage studies of its drugs for age-related diseases. The biotech is working on sarcopenia and age-related macular degeneration.